Drug nanocrystals/nanosuspensions for the delivery of poorly soluble drugs

Nanoparticulates as Drug Carriers

Volumn , Issue , 2006, Pages 307-328

  Müller, Rainer H ^a   Junghanns, Jens Uwe A H ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

POORLY SOLUBLE DRUGS;

DRUG DELIVERY;

EID: 84967407676     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9781860949074_0014     Document Type: Chapter

References (67)

1. Speiser PP (1998) Poorly soluble drugs, a challenge in drug delivery, in Müller RH, Benita S and Böhm B (eds.), Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs, Medpharm Scientific Publishers: Stuttgart.
2. Merisko-Liversidge E (2002) Nanocrystals: Resolving Pharmaceutical Formulation Issues Associated with Poorly Water-soluble Compounds in Particles, Marcel Dekker: Orlando.
3. Bangham AD and Haydon DA (1968) Ultrastructure of membranes: Biomolecular organization. Brit Med Bull 24(2):124-6.
4. Anger S (2005) PhD Thesis, in PhD Thesis Pharmaceutical Technology. Freie Universität: Berlin.
5. Müller RH, Lück M and Kreuter J (1998) Arzneistoffträgerpartikel für die gewebsspezifische Arzneistoffapplikation. Europäische Patentschrift, PCT/EP98/06429.
6. Kreuter J, Kharkevich RN and Ivanov DA (1995) Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res 674(1):171-174.
7. Gu Chong-Hui GDJW (2001) Estimating the relative stability of polymorphs and hydrates from heats of solution and solubility data. J Pharm Sci 90(9):1277-1287.
8. Hancock C and Bruno P (2000) What is the True Solubility Advantage for Amorphous Pharmaceuticals? Pharm Res 17(4):397-404.
9. Gassmann P, List M, Schweitzer A and Sucker H (1994) Hydrosols - Alternatives for the Parenteral Applikation of Poorly Water Soluble Drugs. Eur J Pharm Biopharm 40:64-72.
10. List M and Sucker H (1988) Pat.No. GB 2200048.
11. Auweter HB, Haberkorn C, Horn H, Lueddecke D and Rauschenberger V, Patent No. DE19637517A1.
12. Tunick MHVH, Diane L, Cooke PH and Malin EL (2002) Transmission electron microscopy of Mozzarella cheeses made from microfluidized milk. J Agri Food Chem 50(1):99-103.
13. Bruno RPM (1999) Microfluidizer Processor Technology for High Performance Particle Size Reduction, Mixing and Dispersion. Microfluidizer Processor Technology.
14. Sunstrom JEM and Marshik-Guerts B (1996) General Route to Nanocrystalline Oxids by Hydrodynamic Cavitation. Chem. Mater.
15. Gruverman IJ and Thum JR, Production of Nanostructures Under Turbulent Collision Reaction Conditions - Application to Catalysts, Superconductors, CMP Abrasives, Ceramics and other Nanoparticles. Microfluidics Research.
16. Dearns R (2000), Atovaquone pharmaceutical compositions. US patent US 6 018 080.
17. Müller RH, Peters K, Becker R and Kruss B (1995) Nanosuspensions - A Novel Formulation for the i.v. Administration of Poorly Soluble Drugs, in 1st World Meeting of the International Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology hosted by APGI/APV. Budapest.
18. Müller RH, Becker R, Kruss B and Peters K (1999) Pharmaceutical Nanosuspensions for Medicament Administration as Systems with Increased Saturation Solubility and Rate of Solution, in United States Patent 5, 858, 410. USA.
19. Müller RH, Jacobs C and Kayser O (2000) Nanosuspensions for the formulation of poorly soluble drugs, in Nielloud F and Marti-Mestres G (eds.) Pharmaceutical Emulsions and Suspensions, Marcel Dekker.
20. Müller RH, Becker R, Kruss B and Peters K (1994) Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungs-geschwindigkeit. German patent 4440337.2, US Patent 5.858.410 (1999).
21. Müller RH, Dingier A, Schneppe T and Gohla S (2000) Large scale production of solid lipid nanoparticles (SLNTM) and nanosuspensions (DissoCubes™). in Wise D (ed.), Handbook of Pharmaceutical Controlled Release Technology.
22. Müller RH, Jacobs C and Kayser O (2003) DissoCubes - A novel formulation for poorly soluble and poorly bioavailable drugs, in Rathbone MJ, Hadgraft J, Roberts MS (eds.), Modified-Release Drug Delivery Systems, Marcel Dekker.
23. Rabinow BE (2004) Nanosuspensions in Drug Delivery. Nat Rev 3:785-796.
24. Müller RH (2002) Nanopure Technology for the Production of Drug Nanocrystals and Polymeric Particles, in 4th World Meeting ADRITELF/APV/APGI. Florence.
25. Bushrab NF and Müller RH (2003) Nanocrystals of Poorly Soluble Drugs for Oral Administration. New Drugs 5: 20-22.
26. Radtke M (2001) Nanopure™ pure drug nanoparticles for the formulation of poorly soluble Drugs. New Drugs 3: 62-68.
27. Fichera MA, Keck CM and Müller RH (2004) Nanopure Technology - Drug Nanocrystals for the Delivery of Poorly Soluble Drugs, in Particles. Orlando.
28. Fichera MA, Wissing SA and Müller RH (2004) Effect of 4000 Bar Homogenisation Pressure on Particle Diminution in Drug Suspensions, in APV. Nürnberg.
29. Keck CM, Bushrab NF and Müller RH (2004) Nanopure® Nanocrystals for Oral Delivery of Poorly Soluble Drugs, in Particles. Orlando.
30. Müller RH, Mäder K and Krause K (2000) Verfahren zur schonenden Herstellung von hochfeinen Micro-/Nanopartikeln, in PCT Application PCT/EP00/06535: Germany.
31. Kipp JE, Wong JCT, Doty MJ and Rebbeck CL (2003) Microprecipitation Method For Preparing Submicron Suspensions, in United States Patent 6,607,784. Baxter International Inc. (Deerfield, IL): USA.
32. Möschwitzer J and Müller RH (2005) Method for the Production of Ultrafine Submicron Nanosuspensions (Pat. Application).
33. Möschwitzer J (2005) PhD Thesis in Preparation, in PhD Thesis Pharmaceutical Technology. Freie Universität: Berlin.
34. Möschwitzer J and Müller RH (2005) Effective production of ibuprofen drug nanocrystals by high pressure homogenization using new two-step process, in AAPS. submitted. Nashville.
35. Möschwitzer J and Müller RH (2005) Development of a new two-step process for the effective production drug nanocrystals by high pressure homogenization. in AAPS. submitted. Nashville.
36. Bushrab NF (2005) PhD Thesis in preparation, in PhD Thesis Pharmaceutical Technology. Freie Universität: Berlin.
37. Möschwitzer J and Müller RH (2004) From the Drug Nanocrystal to the Final Mucoadhesive oral Dosage Form, in International Meeting on Pharmaceutics, Biopharmaceutics & Pharmaceutical Technology. Nürnberg.
38. Möschwitzer J and Müller RH (2004) Nanosuspensions as Formulation Principle for Chemical Stabilization of Chemically Labile Drugs, in International Meeting on Pharmaceutics, Biopharmaceutics & Pharmaceutical Technology. Nürnberg.
39. Wua YL, Landisb A, Hettricka E, Novaka L, Lynna L, Chenc K, Thompson A, Higgins R, Batrad U, Shelukard S, Kweia G and Storeye G (2004) The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: A Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm 285(1-2):135-146.
40. Liversidge GGCP (1995) Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm 125:309-313.
41. Müller RH (1997) Preparation in Form of a Matrix Material-Auxiliary Agent Compound Containing Optionally an Active Substance: Europe.
42. Keck CM et al. (2004) Production and Optimisation of Oral Cyclosporine Nanocrystals, in AAPS. Baltimore.
43. Krause K (2004) Herstellung hochfeiner Polymer- und Arzneistoffdispersionen und deren Sprühtrocknung, in PhD Thesis Pharmaceutical Technology, Freie Universität: Berlin.
44. Khar A (2002) Nanoedge Technologies. Baxter Company Booklet.
45. Yamaguchi H and Hachioji I (2001) New antifungal agents currently under clinical development. Nippon Kagaku Ryoho Gakkai Zasshi 9(49):535-545.
46. Slain DR, Cleary PD and Chapman SW (2001) Intravenous itraconazole. Annals of pharmacotherapy 35(6):720-729.
47. Smith A and Hunneyball LM (1986) Evaluation of poly(lactic acid) as a biodegradable drug delivery system for parenteral administration. Int J Pharm 30(2-3):215-220.
48. Hernández-Trejo N, Kayser O, Müller RH and Steckel H (2004) Physical Stability of Bupar-vaquone Nanosuspensions Following Nebulization with Jet and Ultrasonic Nebulizers. Proceedings of the International Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Nuremberg Germany.
49. Hernández-Trejo N, Kayser O, Müller RH and Steckel H (2004) Characterization of nebulized buparvaquone nanosuspensions - Effect of nebulization technology. Pharm Res. submitted.
50. Patravale VBD, Abhijit A and Kulkarni RM (2004) Nanosuspensions: A promising drug delivery strategy. J Phar Pharmacol 56(7):827-840.
51. Pignatello R and Puglisi G (2002) Ocular tolerability of Eudragit RS100 and RL100 nanosuspensions as carriers for ophthalmic controlled drug delivery. J Pharm Sci 91(12):2636-41.
52. Bucolo CM, Puglisi G and Pignatello R (2002) Enhanced ocular anti-inflammatory activity of ibuprofen carried by an Eudragit RSIOO nanoparticle suspension. Ophthal Res 34(5):319-323.
53. Münster UN, Haberland C, Jores A, Mehnert W, Rummel S, Schaller K, Korting M, Zouboulis Ch, Blume-Peytavi C and Schäfer-Korting M (2005) RU 58841-myristate-prodrug development for topical treatment of acne and androgenetic alopecia. Die Pharmazie 60(1):8-12.
54. Maia C, Mehnert W and Schäfer-Korting M (2000) Solid lipid nanoparticles as drug carriers for topical glucocorticoids. Int J Pharm 196:165-167.
55. Müller RH (2001) Dispersions for the Formulation of Slightly or Poorly Soluble Drugs, in PCT/EP01/08726. PharmasSol GmbH Berlin.
56. Müller RH et al. (2004) SolEmuls - A novel technology for the formulation of i.v. emulsions with poorly soluble drugs. Int J Pharm 269:293-302.
57. Muller RH et al. (2004) SolEmuls-novel technology for the formulation of i.v. emulsions with poorly soluble drugs. Int J Pharm 269(2):293-302.
58. Buttle I (2004) O/W-Emulsionen fiir die intravenöse Applikation von Arzneistoffen, in PhD Thesis Pharmaceutical Technology, Freie Universität: Berlin.
59. Akkar A and Müller RH (2004) Solubilisation by Emulsification. Pharm. Ind. 66(12): 1537-1544.
60. Akkar A and Müller RH (2003) Intravenous itraconazole emulsions produced by SolEmuls technology. Eur J Pharm Biopharm 56(1):29-36.
61. Akkar A et al. (2004) Solubilising Poorly Soluble Antimycotic Agents by Emulsification via a Solvent-Free Process. AAPS PharmSciTechpending, submitted.
62. Akkar A and Müller RH (2003) Formulation of intravenous Carbamazepine emulsions by SolEmuls technology. Eur J Pharm Biopharm 55(3):305-12.
63. Akkar A (2004) Poorly Soluble Drugs: Formulation by Nanocrystals and SolEmuls Technologies, in PhD Thesis Pharmaceutical Technology. Freie Universität: Berlin.
64. Hann IM and Prentice HG (2001) Lipid-based amphotericin B: A review of the last 10 years of use. Int J Antimicrob Agents (17): 161-169.
65. Lewis R (2003) Antifungal therapy cost analysis (Patterson T. F. and McGinis M. R., ed.). www.doctorfungus.org.
66. Janoff A et al. (1993) Amphotericin b lipidcomplex (ABLC (TM)): A molecular rationale for the attenuation of amphotericin B related toxicities. J Liposome Res 3:451-471.
67. Davis SS and Washington C (1988) EP 0 296 845 A1.